Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert(Centre Hospitalier de Versailles), Sylvie Castaigné(Hôpital André Mignot), Claude Preudhomme(Centre Hospitalier Universitaire de Lille), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), Ollivier Legrand(Inserm), Rebecca Benner(Brigham and Women's Hospital), Cécile Pautas(Centre Hospitalier Universitaire Henri-Mondor), Sylvie Chevret(Saint Louis University Hospital), Claude Gardin(Sorbonne Université), Pierre Bousset(Pfizer (France)), Emmanuel Raffoux(Inserm), Xavier Thomas(Hôpital Lyon Sud), Karïn Gogat-Marchant(Pfizer (France)), Denis Caillot, Hervé Dombret(Université Paris Cité), Stephen D. Rubin(Pfizer (United States)), Christine Terré(Hôpital André Mignot)
Cited by 349
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k